INTRODUCTION
MicroRNA (miRNA) is a novel family of endogenous small RNA (~21 nt) present in both plants and animals. The miRNA genes are located often in intergenic regions (between coding genes in the genome) and sometimes in the intron of a coding gene. Like mRNA, miRNA is initially transcribed by RNA polymerase II (pol II) into primary miRNA (pri-miRNA) that is also modified to have a cap structure at the 5" end and a poly (A) tail at the 3"end. The pri-miRNAs are processed in the nucleus by the RNase III enzyme, Drosha, and the doublestranded-RNA-binding protein, Pasha (also known as DiGeorge syndrome critical region 8 (DGCR8), into ~70-nucleotide pre-miRNAs, which fold into imperfect stem-loop structures. The premiRNAs are then exported into the cytoplasm by the RAN GTP-dependent transporter exportin-5 and undergo an additional processing step in which a double-stranded RNA of ~22 nucleotides in length, referred to as the miRNA: miRNA* duplex, is excised from the pre-miRNA hairpin by another RNAse III enzyme, Dicer (Lagos-Quintana, Rauhut, Meyer, Borkhardt, & Tuschl, 2003; LagosQuintana, Rauhut, Lendeckel, & Tuschl, 2001 ). Subsequently, the miRNA: miRNA*duplex is incorporated into the miRISC complex. Slack and Weidhaas (2006) , pointed out the mature miRNA strand is preferentially retained in the functional miRISC complex and negatively regulates its target genes.
MICRORNAS AND CANCER
Cancer has recently surpassed heart disease as the leading cause of death in Americans under the age of 80 years. This staggering statistic is highlighted in the case of lung cancer. Lung cancer is the leading cause of cancer deaths in the USA with approximately 170,000 newly diagnosed cases each year (Forgacs, Zochbauer-Muller, Olah, & Minna, 2001 ). Despite the use of surgery, chemotherapy and radiation in the treatment of lung cancer, the survival rate for patients remains extremely poor. Misregulation of genes that control cell-cycle and cell-fate determination often contributes to cancer.
The role of miRNAs in various facets of human tumorigenesis, (such as cell proliferation, differentiation, invasion, apoptosis, angiogenesis, migration, and motility) begs the question whether reverting these anomalies of the miRNome can be effectively harnessed for therapeutic gains? Promising preclinical data from many groups encourage this hypothesis and provide the biological enthusiasm for clinical studies in this direction. Re-introduction of miRNAs down-regulated in cancer (e.g. miR-15a and miR-16 in BCL2 positive CLL) and/or silencing of miRNAs up-regulated in the tumor (e.g. miR-34 and let-7 in lung cancer) may drive apoptosis in cancer cells and lead to a desirable therapeutic outcome (Slack & Weidhaas, 2006) . This work would focus on two important microRNAs miR-21 and miR-155 known to be differentially expressed in cancers.
MIR-21 AND CANCER
According to published sequence data in miRbase, the MIR-21 gene is located in an intergenic region. The length of the gene is reported as 3433 nucleotides long. It overlaps with the 3' UTR end of the Transmembrane Protein 49 (TMEM 49) (also known as Human Vacuole Membrane Protein 1, VMP-1). It is suggested that RNA Pol II is the most likely enzyme involved in miRNA transcription. However, studies provide evidences for RNA Pol III dependent transcription of few miRNAs interspersed among repetitive Alu elements. As reported in the mirBase, the primary transcripts of microRNAs are processed by enzymatic microprocessor Drosha (RNase III enzyme) and DGCR8 (dsRNA binding protein) from their 3' and 5' cleavage sites into an intermediate stem-loop precursor or pre-miRNA in the nucleus. The precursor of MIR-21 is 72 bases long (pre-MIR-21), forms a secondary structure, and contains the mature miRNA sequence, stem and terminal loop structures with 2-nt 3'overhang The precursor is then transferred from nucleus to cytoplasm by the enzyme Exportin 5. In cytoplasm, a second RNase III enzyme, Dicer, removes terminal loop generating about 20-bp RNA duplex. The length is said to be about 72 bases. The mature miRNA forms one strand of the RNA duplex. One strand is degraded and other is incorporated in to a protein complex, RNA induced silencing complex (RISC), targeting a partially complementary target mRNA. MIR-21 is 22 nucleotides long. A number of reports from many groups show that "several tumor suppressors including phosphatase and tensin homolog known to be deleted on chromosome ten (PTEN) (Meng et MiR-21, in particular, is known to be highly expressed in various cancer types. MicroRNA functions can be cell context and tissue-dependent. For example, Lu and colleagues reported that the inhibition of miR-21using anti-sense oligonucleotides increased the growth of HeLa cells (derived from cervical cancer) but did not significantly affect the growth of A549 cells (non-small cell lung cancer; (Lu et al., 2005) . The inhibition of miR-21 resulted in increased apoptosis in human glioblastoma cells.
MiR-21 is thought to play a significant role in the drug resistance to cisplatin in the neuroblastoma cells.
Higher levels of miR-21 are reported in the serum and tumours of patients with cancer. Upon returning miR-21 to endogenous levels the mouse tumours disappeared. Notably, this was the first report indicating the addiction of tumours to a single oncogenic miRNA (termed "oncomir addiction"). Ubiquitous expression of miR-21, fourfold to sixfold over endogenous levels, resulted in no obvious phenotypes; however, miR-21 overexpression could potentiate the phenotype of mice with a latent KrasG12D allele (KrasLA2), a constitutively activated version of the KRAS proto-oncoprotein. Doubly transgenic animals had an increased lung tumour burden relative to the KrasLA2 mice, but no increase in the rate of conversion from adenoma to adenocarcinoma. By contrast, the lung tumour burden was decreased in KrasLA2; miR-21animals, relative to the KrasLA2 controls. Contrary to earlier report (Hatley et al., 2010), Liu and co-workers showed that miR-21 is involved in the later stages of tumorigenesis and not in tumour promotion, as it has no effect on tumorigenesis in the absence of oncogenic KRAS. These studies, combined with human tissue data and cell culture experiments, confirm that miR-21 is an oncogene and provide a rationale for the therapeutic inhibition of miR-21.
According to Liu and co-workers (Liu et al., 2012) , MiR-21 is a miRNA which has been reported to be overexpressed in many human malignancies including Non-small cells lung cancer, NSCLC. In their previous studies, they showed that upregulation of miR-21 in NSCLC serum is correlated with TNM stage and lymph node metastasis (Wang et al., 2011; Fu et al., 2011). Furthermore, the status of serum miR-21 expressions is found to be an independent prognostic factor for NSCLC patients. . miR-155 is regarded as "masterregulator" of many biological processes. It is a prominent microRNA (miRNA) that regulates genes involved in immunity and cancer-related pathways. MiR-155 is said to be overexpressed in lung cancer, which correlates with poor patient prognosis. It is unclear how miR-155 becomes increased in lung cancers and how this increase contributes to reduced patient survival. The crucial role of miR-155 is further underscored by independent generation of transgenic, mir-155-overexpressing mice and mir-155-knockout mice which demonstrated that this gene is important in the immune system. Wild-type levels of miR-155 are essential for preserving normal immune system function, including the maintenance of both major classes of cells (B and T lymphocytes) of the adaptive immune response and dendritic cells, which are involved in the innate immune response. Although mir-155-knockout mice are immunocompromised owing to defects in these cell lineages, overexpression of miR-155 specifically in the B cell lineage results in preleukaemic pre-B cell proliferation in the spleen and bone marrow, followed later in life by B cell malignancy.
